Outcomes of patients treated with anti-CD30 CAR T- cell have been disappointing in relapsing/refractory (r/r) classical Hodgkin’s Lymphoma (cHL). The gene discussed is TNFRSF8; the disease is classic Hodgkin lymphoma.